# Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

> **NCT01283594** · PHASE2,PHASE3 · COMPLETED · sponsor: **Biotie Therapies Inc.** · enrollment: 420 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Tozadenant (SYN115) 60 mg BID
- **DRUG:** Placebo
- **DRUG:** Levodopa (L-dopa)
- **DRUG:** Tozadenant (SYN115) 120 mg BID
- **DRUG:** Tozadenant (SYN115) 180 mg BID
- **DRUG:** Tozadenant (SYN115) 240 mg BID

## Key facts

- **NCT ID:** NCT01283594
- **Lead sponsor:** Biotie Therapies Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2019-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283594, "Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01283594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*